Results 191 to 200 of about 94,283,903 (258)

Effect of the gut microbiota metabolite phenylacetylglycine on cardiac Ca²⁺ signaling. [PDF]

Biophys Rep (N Y)
Bovo E, Zima AV.
europepmc   +1 more source

Sex Differences in Prescribing Patterns of Anticholinergics and β3-Adrenoceptor Agonists for Overactive Bladder: A Nationwide Study in Japan, FY2017-FY2024. [PDF]

Low Urin Tract Symptoms
Koike T, Kawahara T, Hashizume A, Yamazaki M, Takamoto D, Ito H, Takeshima T, Uemura H, Makiyama K, Teranishi JI.   +9 more
europepmc   +1 more source

Mirabegron administration for the prevention of ureteral injuries during ureteral access sheath insertion. [PDF]

World J Urol
Ermiş O, Sabuncu K, Kaçtan Ç, Karakuş B, Sürmeli B, Boz MY, Horuz R.   +6 more
europepmc   +1 more source

Inhaled S-nitrosoglutathione in asthma: Airway SCoR2 expression and determinants of human bronchodilator response. [PDF]

J Allergy Clin Immunol
Gaston B, Smith LA, Zhao Y, Premont RT, Yang F, Chmiel JF, Tilston-Lunel A, Twigg H, Davis MD, Jafri A, Ross K, Giddings O, Raffay TM, Grimmett ZW, Mahan K, Marozkina N, Reynolds JD, Stamler JS.   +17 more
europepmc   +1 more source

Salbutamol and Formoterol Attenuate Okadaic Acid-Induced Cytotoxicity in Undifferentiated PC-12 Cells: Evidence for a β2-Adrenergic Receptor-Independent Protective Component. [PDF]

Curr Issues Mol Biol
Kotsoni A, Ioannou E, Barmparousi E, Zacharia LC.   +3 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Beta-3 Adrenergic Receptor Agonists Cause an Increase in Gastrointestinal Transit Time in Wild-Type Mice, but Not in Mice Lacking the Beta-3 Adrenergic Receptor

Journal of Pharmacology and Experimental Therapeutics, 1998
The effects of beta-3 adrenergic receptor (beta3-AR) agonists on gastrointestinal (GI) motility, as reported by stomach retention and intestinal transit of radiolabelled charcoal, were compared in wild-type (WT) mice and in transgenic mice lacking beta3-AR (beta3-AR[KO]) or having beta3-AR in white and brown adipose tissue only (beta3-AR[WAT+BAT ...
Bradford B Lowell, Danica Grujić, M R Candelore   +2 more
exaly   +3 more sources

Beta-3 adrenergic receptor agonist for adult with overactive bladder

Cochrane Database of Systematic Reviews, 2015
This is the protocol for a review and there is no abstract. The objectives are as follows: General objective Yo assess the overall effects of treatment with beta-3 adrenergic receptor agonists in adults with OAB by doing a systematic review and meta-analysis of all available RCTs.
Michael Erlano Chua, Marie Carmela M Lapitan, Jan Michael A Silangcruz, Saturnino Luna Jr., Marcelino Lopeztan Morales Jr.   +4 more
openaire   +1 more source

Potent benzimidazolone based human β3-adrenergic receptor agonists

Bioorganic & Medicinal Chemistry Letters, 2006
The synthesis and biological evaluation of a series of benzimidazolone beta(3) adrenergic receptor agonists are described. A trend toward the reduction of rat atrial tachycardia upon increasing steric bulk at the 3-position of the benzimidazolone moiety was observed.
Don R, Finley, Michael G, Bell, Anthony G, Borel, William E, Bloomquist, Marlene L, Cohen, Mark L, Heiman, Aidas, Kriauciunas, Donald P, Matthews, Tania, Miles, David A, Neel, Christopher J, Rito, Daniel J, Sall, Anthony J, Shuker, Thomas W, Stephens, Frank C, Tinsley, Mark A, Winter, Cynthia D, Jesudason   +16 more
openaire   +2 more sources

Potent, selective benzenesulfonamide agonists of the human β3 adrenergic receptor

Bioorganic & Medicinal Chemistry Letters, 1998
A cloned human beta 3 adrenergic receptor assay was used to identify phenoxypropanolamine agonist 1. SAR studies led to the identification of benzenesulfonamide derivative 20, a 6.3 nM beta 3 agonist which shows 30-fold selectivity for beta 3 agonist activity over beta 1 and beta 2 receptor binding.
A E, Weber, R J, Mathvink, L, Perkins, J E, Hutchins, M R, Candelore, L, Tota, C D, Strader, M J, Wyvratt, M H, Fisher   +8 more
openaire   +2 more sources

Metabolic alterations associated with the antidiabetic effect of beta 3-adrenergic receptor agonists in obese mice

American Journal of Physiology-Endocrinology and Metabolism, 1995
Treatment of obese (ob/ob) mice with the beta 3-adrenergic receptor (beta 3-AR) agonist BRL-35135 (1 mg.kg body wt-1.day-1 for 20 days) normalized plasma glucose levels and significantly decreased plasma insulin and nonesterified fatty acid levels.
C M, Arbeeny, D S, Meyers, D E, Hillyer, K E, Bergquist   +3 more
openaire   +2 more sources